The ReadoutThe NASH gold rush is waning, Zolgensma turns 2, & the dawn of federal biotech bonds By Damian Garde May 25, 2021 Reprints Alex Hogan/STAT The Readout for May 25, 2021 About the Author Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Business Bob Herman and Casey Ross STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Special Report Jason Mast, Allison DeAngelis and Megan Molteni STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
